Short Interest in Marker Therapeutics, Inc. (NASDAQ:MRKR) Declines By 35.5%

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 149,800 shares, a drop of 35.5% from the January 31st total of 232,100 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average trading volume of 77,600 shares, the days-to-cover ratio is presently 1.9 days.

Insider Buying and Selling

In related news, major shareholder Enterprise Associates 16 New acquired 554,250 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average price of $3.20 per share, for a total transaction of $1,773,600.00. Following the completion of the acquisition, the insider now owns 1,625,678 shares of the company’s stock, valued at approximately $5,202,169.60. This represents a 51.73 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steve Elms acquired 11,085 shares of the stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $3.20 per share, for a total transaction of $35,472.00. Following the transaction, the director now owns 325,370 shares of the company’s stock, valued at approximately $1,041,184. This trade represents a 3.53 % increase in their position. The disclosure for this purchase can be found here. 14.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Marker Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invst LLC purchased a new stake in shares of Marker Therapeutics during the 3rd quarter valued at approximately $56,000. LPL Financial LLC bought a new stake in Marker Therapeutics during the 4th quarter valued at $248,000. Aisling Capital Management LP lifted its position in shares of Marker Therapeutics by 3.5% during the fourth quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after acquiring an additional 11,084 shares in the last quarter. Blue Owl Capital Holdings LP bought a new position in shares of Marker Therapeutics in the fourth quarter worth $1,724,000. Finally, Northern Trust Corp boosted its holdings in shares of Marker Therapeutics by 66.9% in the fourth quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after acquiring an additional 21,703 shares during the period. Institutional investors own 22.39% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Brookline Capital Management raised Marker Therapeutics to a “strong-buy” rating in a report on Monday, February 10th.

Marker Therapeutics Price Performance

Shares of MRKR opened at $1.53 on Friday. Marker Therapeutics has a fifty-two week low of $1.45 and a fifty-two week high of $5.99. The business has a 50-day moving average of $2.30 and a 200 day moving average of $3.02.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.